Illumina said today it will acquire GenoLogics Life Sciences Software, a developer of laboratory information management systems (LIMS) for life science organizations, in a deal intended to strengthen the buyer’s portfolio of genetic analysis solutions. The price was not disclosed.
GenoLogics’ Clarity LIMS™ software, adopted by more than 120 genomic labs worldwide, is designed to enable lab efficiencies and improved sample throughput with increased accuracy, fast turnaround, sample traceability, and preconfigured instrument integrations.
“Adding GenoLogics’ products to Illumina’s portfolio is another example of our continued commitment to bring innovative sample-to-answer solutions to research and clinical labs,” Illumina President Francis DeSouza said in a statement. “The acquisition of GenoLogics demonstrates Illumina's commitment to drive the adoption of sequencing in new markets and improve the genomic information workflow."
Added GenoLogics CEO Michael Ball: “This acquisition will enable us to widen our distribution, accelerate our product development, and provide even greater support to the Clarity LIMS community."
Illumina said the deal is expected to close by the end of August, and builds on years of partnerships between the companies. In 2011, Illumina became an investor in GenoLogics by leading an $8 million financing round. GenoLogics said at the time it would use the funding to accelerate product development for future clinical applications and new desktop sequencing systems.
A more recent example of a partnership involving the companies is Clarity LIMS X, an edition of its laboratory informatics platform launched on July 20. Optimized for use with Illumina SeqLab, Clarity LIMS X is designed to provide rapid scaling with automation and business logic built into preconfigured HiSeq X Series workflows. Clarity LIMS X Edition also provides e-signature, audit trails, and patient data security, with the goal of being suitable for regulated environments.
GenoLogics will become part of the Illumina Enterprise Informatics business to be led by Sanjay Chikarmane, svp and general manager of enterprise informatics.
Illumina said it accounted for the GenoLogics acquisition in updating its 2015 financial guidance to investors on July 21. The sequencing giant raised its projections for non-GAAP earnings per diluted share to between $3.39 and $3.45—up from between $3.36 and $3.42 as April 21, when first-quarter results were released, and well above the $3.12 to $3.18 range initially projected for 2015 when fourth-quarter and full-year 2014 results were released on January 27.